The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

China’s NMPA has granted approval for the marketing authorisation application of Santen Pharmaceutical's Tapcom.

Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

With an increasing demand for NHS services, technology is being positioned as a critical tool in eliminating inefficiencies ...